retatrutide vs glp 3 What GLP‑3 Really Is: Triple‑Receptor Drug How Does Retatrutide Work? The

In their respective obesity programmes the triple agonist reported larger mean reductions: retatrutide reached about 24.2% at 48 weeks in Phase 2 (NEJM 2023) and 28.3% at 80 weeks in Phase 3 TRIUMPH-1, while tirzepatide reported about 20.9% at 72 weeks in SURMOUNT-1

Here is what the research supports and what it does not

To help preserve muscle while on GLP-1 medications, focus on eating enough protein and making strength training part of your regular routine

Symptoms were rated as mild to moderate in nearly all reported cases, and nobody in the available research stopped using the medication because of skin-related issues alone